APCER Life Sciences Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2015
NCT02547818
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

APCER | APCER Life Sciences

Active Ingredients

Drugs in Phase 3 Trials (2)

cromoglicic acid (Intal) (2 trials)

ibuprofen (motrin) (1 trial)

Drugs in Phase 2 Trials (1)

etripamil (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 3)

Atrial Fibrillation (Phase 2)

Cerebral Infarction (Phase 2)

Cognitive Dysfunction (Phase 2)

Ischemia (Phase 2)

Stroke (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 3